CD4 News and Research

RSS

Changes to COVID-19 vaccination strategy could speed up herd immunity

Researchers in the United States have proposed changes to the current coronavirus disease 2019 (COVID-19) vaccination strategy that they say would increase the likelihood of herd immunity being achieved in the most timely and cost-effective manner.

8 Jul 2021

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

6 Jul 2021

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

Researchers in the Netherlands have conducted a study showing that Janssen’s Ad26.COV2.S coronavirus disease 2019 (COVID‐19) vaccine was effective against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among eight individuals.

4 Jul 2021

B cell depleting agents can cause altered immune responses to COVID-19 vaccines, suggests study

A new preprint, available on the medRxiv* server, describes altered responses to the use of the highly effective messenger RNA (mRNA) vaccines from Pfizer/BioNTech and Moderna in patients with multiple sclerosis on anti-CD20 (MS-aCD20) monotherapy.

2 Jul 2021

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

In a paper recently uploaded to the preprint server bioRxiv* by Schamel et al. (June 25th, 2021) engineered T cells against SARS-CoV-2 are tested against a range of cells in vitro, finding that the treatment could be used to restore cellular immune function and suppress SARS-CoV-2.

1 Jul 2021

Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections

Researchers at La Jolla Institute for Immunology have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

1 Jul 2021

What's behind COVID-19 vaccine side effects?

A growing concern among coronavirus vaccines is the vaccine side effects. Fear or misinformation about side effects may fuel vaccine hesitancy, contributing to low vaccination rates. Australian researchers recently published an article in Science Immunology to discuss why people develop side effects and their benefits.

28 Jun 2021

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Researchers compared peripheral blood mononuclear cells in people with high and low antibody titers after two doses of the Pfizer/BioNTech (BNT162b2) mRNA vaccine. They found a positive correlation between naïve B cells present before vaccination and high antibody titers.

28 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

A recent study conducted by an international team of scientists has revealed that the Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccine, AZD1222, is capable of inducing strong spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses in vaccinated individuals. A detailed description of AZD1222-induced cellular immunity is currently available on the medRxiv* preprint server.

28 Jun 2021

TET enzymes play key role in keeping immune cells on a healthy track

Researchers at La Jolla Institute for Immunology (LJI) have shed light on a process in immune cells that may explain why some people develop cardiovascular diseases.

25 Jun 2021

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

CD39+ monocyte count higher in pregnant than non-pregnant COVID-19 patients

A new study published on the bioRxiv* server describes the changes in the representation of a subset of activated monocytes in this group of patients.

23 Jun 2021

Cancer immunotherapy may self-limit its efficacy in fighting tumors, study finds

Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni, Ph.D., assistant professor of physiology & biophysics and member of the Institute for Immunology at the University of California, Irvine.

22 Jun 2021

Study shows activation of CD16+ T-cells contribute to severe COVID-19 illness

Do T-cells play a protective immune role, or are they responsible for severe COVID-19 illness?

21 Jun 2021

Different comorbid conditions in COVID-19 patients can impact outcomes of positive PCR test results

New study results indicate that different comorbid conditions affecting individuals diagnosed with COVID-19 may impact how long they continue to receive positive SARS-CoV-2 polymerase chain reaction (PCR) test results.

17 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

It has been uncertain whether antibodies produced via this non-canonical pathway are protective against SARS-CoV-2. In a new study, recently released as a preprint on the bioRxiv*server, the neutralization potency of these antibodies is compared with those traditionally produced in germinal center-based antiviral responses.

15 Jun 2021

Immune memory responses differ between SARS-CoV-2 and influenza A

Researchers in Canada have shown that the long-lasting immunity that develops following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by different T cell responses than those observed for influenza A virus-specific immune memory.

14 Jun 2021

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

CD4 News and Research

Changes to COVID-19 vaccination strategy could speed up herd immunity

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

B cell depleting agents can cause altered immune responses to COVID-19 vaccines, suggests study

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections

What's behind COVID-19 vaccine side effects?

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

TET enzymes play key role in keeping immune cells on a healthy track

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

CD39+ monocyte count higher in pregnant than non-pregnant COVID-19 patients

Cancer immunotherapy may self-limit its efficacy in fighting tumors, study finds

Study shows activation of CD16+ T-cells contribute to severe COVID-19 illness

Different comorbid conditions in COVID-19 patients can impact outcomes of positive PCR test results

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

Immune memory responses differ between SARS-CoV-2 and influenza A

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News